Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2-/-γc-/-) mouse model

Gene Therapy

Volumn 16, Issue 1, 2009, Pages 148-153

  ter Brake, O ^a   Legrand, N ^a   von Eije, K J ^a   Centlivre, M ^a   Spits, H ^a   Weijer, K ^a   Blom, B ^a   Berkhout, B ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; NEF PROTEIN; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EX VIVO STUDY; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE SYSTEM; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; VIRAL GENE THERAPY; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; GENE EXPRESSION; GENE THERAPY; GENES, NEF; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTES;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 58149458865     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.124     Document Type: Article

References (35)

1. Deeks SG. Antiretroviral treatment of HIV infected adults. BMJ 2006; 332: 1489.
2. Richman DD. HIV chemotherapy. Nature 2001; 410: 995-1001.
3. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE et al The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44: 990-997.
4. Strayer DS, Akkina R, Bunnell BA, Dropulic B, Planelles V, Pomerantz RJ et al. Current status of gene therapy strategies to treat HIV/ AIDS. Mol Ther 2005; 11: 823-842.
5. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
6. Wolkowicz R, Nolan GP. Gene therapy progress and prospects: Novel gene therapy approaches for AIDS. Gene Therapy 2005; 12: 467-476.
7. Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435-438.
8. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004; 78: 2601-2605.
9. ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: A multiple shRNA approach. Mol Ther 2006; 14: 883-892.
10. Chang LJ, Liu X, He J. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1. Gene Therapy 2005; 12: 1133-1144.
11. Westerhout EM, Ooms M, Vink M, Das AT, Berkhout B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res 2005; 33: 796-804.
12. Lackner AA, Veazey RS. Current concepts in AIDS pathogenesis: Insights from the SIV/macaque model. Annu Rev Med 2007; 58: 461-476.
13. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427: 848-853.
14. Dias AS, Bester MJ, Britz RF, Apostolides Z. Animal models used for the evaluation of antiretroviral therapies. Curr HIV Res 2006; 4 431-446.
15. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, Lanzavecchia A et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004; 304 104-107.
16. -/- mice: functional inactivation of p53 in developing T cells. Blood 2004; 104: 3886-3893.
17. Legrand N, Weijer K, Spits H. Experimental models to study development and function of the human immune system in vivo. J Immunol 2006; 176: 2053-2058.
18. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7: 118-130.
19. Manz MG. Human-hemato-lymphoid-system mice: Opportunities and challenges. Immunity 2007; 26: 537-541.
20. Legrand N, Cupedo T, van Lent AU, Ebeli MJ, Weijer K, Hanke T et al Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in 'human immune system' Rag2(-/-)gammac(-/ -) mice. Blood 2006; 108: 238-245.
21. -/- mice. Proc Natl Acad Sci USA 2006; 103: 15951-15956.
22. Zhang L, Kovalev GI, Su L. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 2007; 109: 2978-2981.
23. Watanabe S, Terashima K, Ohta S, Horibata S, Yajima M, Shiozawa Y et al. Hematopoietic stem cell-engrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood 2007; 109: 212-218.
24. -/- (RAG-hu) mouse model. Retrovirology 2006; 3: 76.
25. An DS, Poon B, Ho Tsong FR, Weijer K, Blom B, Spits H et al. Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2007; 14: 391-396.
26. -/-) (RAG-hu) mice. Virology 2008; 373: 342-351.
27. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
28. Seppen J, Rijnberg M, Cooreman MP, Oude Elferink RP. Lentiviral vectors for efficient transduction of isolated primary quiescent hepatocytes. J Hepatol 2002; 36: 459-465.
29. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L et al Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
30. ter Brake O, Berkhout B. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions. J Gene Med 2007; 9: 743-750.
31. Weijer K, Uittenbogaart CH, Voordouw A, Couwenberg F, Seppen J, Blom B et al. Intrathymic and extrathymic development of human plasmacytoid dendritic cell precursors in vivo. Blood 2002; 99 2752-2759.
32. Anderson J, Li MJ, Palmer B, Remling L, Li S, Yam P et al. Safety and efficacy of a lentiviral vector containing three anti-HIV genes - CCR5 ribozyme, tat-rev siRNA, and TAR decoy - in SCID-hu mouse-derived T cells. Mol Ther 2007; 15: 1182-1188.
33. An DS, Donahue RE, Kamata M, Poon B, Metzger M, Mao SH et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci USA 2007; 104: 13110-13115.
34. Grimm D, Kay MA. Combinatorial RNAi: A winning strategy for the race against evolving targets? Mol Ther 2007; 15: 878-888.
35. ter Brake O, t Hooft K, Liu YP, Centlivre M, von Eije KJ, Berkhout B. Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther 2008; 16: 557-564.